SG11201601807XA - Methods for treating chronic obstructive pulmonary disease using benralizumab - Google Patents

Methods for treating chronic obstructive pulmonary disease using benralizumab

Info

Publication number
SG11201601807XA
SG11201601807XA SG11201601807XA SG11201601807XA SG11201601807XA SG 11201601807X A SG11201601807X A SG 11201601807XA SG 11201601807X A SG11201601807X A SG 11201601807XA SG 11201601807X A SG11201601807X A SG 11201601807XA SG 11201601807X A SG11201601807X A SG 11201601807XA
Authority
SG
Singapore
Prior art keywords
benralizumab
methods
pulmonary disease
chronic obstructive
obstructive pulmonary
Prior art date
Application number
SG11201601807XA
Other languages
English (en)
Inventor
Der Merwe Rene Van
Christine Ward
Ubaldo Martin
Lorin Roskos
Bing Wang
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of SG11201601807XA publication Critical patent/SG11201601807XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201601807XA 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab SG11201601807XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US201461970126P 2014-03-25 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Publications (1)

Publication Number Publication Date
SG11201601807XA true SG11201601807XA (en) 2016-04-28

Family

ID=52809872

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201601807XA SG11201601807XA (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab
SG10201807318RA SG10201807318RA (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201807318RA SG10201807318RA (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Country Status (12)

Country Link
US (4) US20150104447A1 (https=)
EP (2) EP3485902A1 (https=)
JP (3) JP2016534996A (https=)
KR (1) KR20160061352A (https=)
CN (2) CN105636607A (https=)
AU (2) AU2014334563A1 (https=)
BR (1) BR112016008082A2 (https=)
CA (1) CA2925402A1 (https=)
MX (2) MX2016004329A (https=)
RU (1) RU2706729C2 (https=)
SG (2) SG11201601807XA (https=)
WO (1) WO2015057668A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014177459A2 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
MX380658B (es) 2014-01-15 2025-03-11 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
AU2016272399B2 (en) 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
AU2020398168A1 (en) * 2019-12-06 2022-07-28 Regeneron Pharmaceuticals, Inc. Methods for treating COPD by administering an IL-33 antagonist
EP3957308A1 (en) * 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
CA3223191A1 (en) * 2021-09-03 2023-03-09 University Of Utah Research Foundation Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
CA2704600C (en) * 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US7404953B2 (en) * 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
MX376656B (es) * 2007-05-14 2025-03-07 Kyowa Kirin Co Ltd Metodos para reducir niveles de basófilos.
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
WO2012049278A1 (en) * 2010-10-15 2012-04-19 Medimmune Limited Therapies for improving pulmonary function
RU2578468C2 (ru) * 2010-12-16 2016-03-27 Дженентек, Инк. Способы диагностики и лечения, связанные с ингибированием th2
WO2012158954A1 (en) * 2011-05-18 2012-11-22 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
US20140328839A1 (en) * 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
AU2014306956B2 (en) * 2013-08-12 2019-11-21 Astrazeneca Ab Methods for reducing exacerbation rates of asthma using benralizumab
RU2728578C2 (ru) * 2013-08-12 2020-07-30 Астразенека Аб Способы нормализации симптомов астмы с применением бенрализумаба
SMT202100152T1 (it) * 2013-08-12 2021-05-07 Astrazeneca Ab Metodi per aumentare il volume espiratorio forzato negli asmatici utilizzando benralizumab

Also Published As

Publication number Publication date
SG10201807318RA (en) 2018-09-27
AU2020202333A1 (en) 2020-04-23
CA2925402A1 (en) 2015-04-23
EP3485902A1 (en) 2019-05-22
MX2016004329A (es) 2016-11-10
BR112016008082A2 (pt) 2017-10-17
US20170107291A1 (en) 2017-04-20
WO2015057668A1 (en) 2015-04-23
JP2016534996A (ja) 2016-11-10
CN105636607A (zh) 2016-06-01
US20150104447A1 (en) 2015-04-16
MX2019013468A (es) 2020-02-12
RU2016118425A (ru) 2017-11-21
JP6870037B2 (ja) 2021-05-12
JP2019203009A (ja) 2019-11-28
RU2706729C2 (ru) 2019-11-20
EP3057609A1 (en) 2016-08-24
AU2014334563A1 (en) 2016-04-07
EP3057609A4 (en) 2017-03-22
US20200123262A1 (en) 2020-04-23
KR20160061352A (ko) 2016-05-31
RU2016118425A3 (https=) 2018-07-19
JP2021107421A (ja) 2021-07-29
CN113230399A (zh) 2021-08-10
US20180291108A1 (en) 2018-10-11

Similar Documents

Publication Publication Date Title
IL292193A (en) Anti-b7–h1 antibodies for the treatment of tumors
IL245193A0 (en) Thoracoscopic methods for the treatment of bronchial disease
SG11201601807XA (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
IL243976A0 (en) kdm1a inhibitors for disease treatment
SG11201600918PA (en) Method for authenticating transactions
ZA201506401B (en) Process for producing hydrocarbons
SG11201508388YA (en) Methods for enhancing aged muscle regeneration
PL3019577T3 (pl) Sposób wytwarzania węglowodorów
SG11201603050TA (en) Methods for treating cancers
SG11201507496UA (en) N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
IL244042A0 (en) A method for treating leiftic disease
IL244118A0 (en) Compounds and methods for the treatment of chronic urticaria
PT3164394T (pt) Inibidores gls1 para o tratamento de doenças
EP2945593A4 (en) METHOD OF LYOPHILIZATION
SG11201600484TA (en) Methods for improving asthma symptoms using benralizumab
LT3016682T (lt) Vėžio gydymo būdai
PL2875049T3 (pl) Sposoby zapobiegania i leczenia przewlekłej choroby nerek (ckd)
IL253325A0 (en) Combined treatment of pulmonary hypertension
TWI563128B (en) Methods for treating aluminum surfaces
GB201217330D0 (en) Therapeutic for treating inflammatory lung disorders
LU92599B1 (en) Oral suspension for treating eosinophilic esophagitis
IL233568A0 (en) A method for treating obstructive lung disease
HK1227729A1 (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
LU92721B1 (en) Oral suspension for treating eosinophilic esophagitis
GB201304811D0 (en) Novel treatment for hypertension